A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of Combined Therapy With ATR Inhibitor AZD6738 and Gemcitabine, Using a Model Based Design
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Ceralasertib (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Acronyms ATRiUM
- 09 Oct 2019 Status changed from not yet recruiting to recruiting.
- 15 Jul 2019 Planned number of patients changed from 50 to 55.
- 15 Jul 2019 Planned End Date changed from 31 Mar 2024 to 30 Sep 2024.